QUESTRAN

Pre-Launch

cholestyramine

Bristol Myers Squibb

ANDAORALTABLET

Lifecycle

Pre-Launch

Clinical Trials

Data completeness

4/8 — Partial

QUESTRAN (cholestyramine) by Bristol Myers Squibb is bile-acid binding activity [moa]. Approved for hypertension.

Drug data last refreshed 1mo ago

$0.0BPart D

Mechanism of Action

Bile-acid Binding Activity

Indications (1)

hypertension

Clinical Trials (4)

NCT05894928Phase 1Completed

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

Started Jun 2023

21 enrolled

Healthy

NCT04235205Phase 2Completed

Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease

Started Jan 2020

102 enrolled

Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis

NCT01122108Phase 4Completed

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

Started Apr 2010

42 enrolled

Healthy

NCT01062269Phase 4Completed

A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study

Started Jan 2010

42 enrolled

Healthy

Worked on QUESTRAN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.